WO2000004892A2 - Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions - Google Patents

Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions Download PDF

Info

Publication number
WO2000004892A2
WO2000004892A2 PCT/US1999/013948 US9913948W WO0004892A2 WO 2000004892 A2 WO2000004892 A2 WO 2000004892A2 US 9913948 W US9913948 W US 9913948W WO 0004892 A2 WO0004892 A2 WO 0004892A2
Authority
WO
WIPO (PCT)
Prior art keywords
acid
methyl
phenyl
biphenyl
hydroxy
Prior art date
Application number
PCT/US1999/013948
Other languages
English (en)
French (fr)
Other versions
WO2000004892A3 (en
Inventor
Thomas Michael Andrew Bocan
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EEP200100046A priority Critical patent/EE200100046A/xx
Priority to APAP/P/2001/002035A priority patent/AP2001002035A0/en
Priority to HR20010055A priority patent/HRP20010055A2/hr
Priority to JP2000560885A priority patent/JP2002521328A/ja
Priority to BR9912296-0A priority patent/BR9912296A/pt
Priority to EA200100153A priority patent/EA200100153A1/ru
Priority to KR1020017000930A priority patent/KR20010083134A/ko
Priority to SK50-2001A priority patent/SK502001A3/sk
Priority to PL99346011A priority patent/PL346011A1/xx
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Priority to AU47017/99A priority patent/AU4701799A/en
Priority to IL14098299A priority patent/IL140982A0/xx
Priority to CA002335062A priority patent/CA2335062A1/en
Priority to EP99930483A priority patent/EP1098662A2/en
Publication of WO2000004892A2 publication Critical patent/WO2000004892A2/en
Publication of WO2000004892A3 publication Critical patent/WO2000004892A3/en
Priority to IS5809A priority patent/IS5809A/is
Priority to BG105162A priority patent/BG105162A/xx
Priority to NO20010291A priority patent/NO20010291D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • Enzymes known as native matrix metalloproteinases are classes of naturally occurring enzymes found in most mammals. They are zinc proteases that hydrolyze collagens, proteoglycans, and glycoproteins. The classes include gelatinase A and B, stromelysin-1 and -2, fibroblast collagenase, neutrophil collagenase, matrilysin, metalloelastase, and interstitial collagenase. These enzymes are implicated in a number of diseases which result from breakdown of connective tissues, such as rheumatoid arthritis, osteoarthritis, osteoporosis, multiple sclerosis, and even tumor metastasis.
  • MMP native matrix metalloproteinases
  • Patent 5,756,545 covers MMP inhibitors especially 2-(4'-Bromo-biphenyl-4-sulfonylamino)-3-methyl-butyric acid. This patent is hereby inco ⁇ orated by reference.
  • Patent 5,441,975 teaches ACAT inhibitors, especially N-(2,6-Diisopropyl-phenyl)-2-(2-dodecyl-2H-tetrazol-5-yl)-2-phenyl-acetamide.
  • ACAT inhibitors especially N-(2,6-Diisopropyl-phenyl)-2-(2-dodecyl-2H-tetrazol-5-yl)-2-phenyl-acetamide.
  • This and other patents in the same patent family: 5,646,170; 5,693,657; and 5,366,987 are hereby inco ⁇ orated by reference.
  • the instant invention is the coadministration of ACAT and MMP inhibitors for the reduction of both macrophage and smooth muscle cell components of atherosclerotic lesions in a mammal, particularly a human.
  • the lesions are directly reduced, and so, the expansion of existing lesions and the development of new ones is impaired.
  • Certain ACAT inhibitors and certain MMP inhibitors are disclosed as suitable for coadministration.
  • compositions of the inhibitors are also included in the invention.
  • ACAT inhibitors have been shown to reduce the accumulation of monocyte-macrophages within atherosclerotic lesions of rabbits.
  • monocyte-macrophages have been reported to secrete such matrix metalloproteinases as MMP-7 and -9 while smooth muscle cells are noted to secrete MMP-1, -2, and -3.
  • Inhibition of ACAT while directly reducing the accumulation of lipid-filled monocyte-macrophages will decrease the source of MMPs.
  • MMP-7 Inhibition of MMPs will also limit the development of atherosclerotic lesions through reducing smooth muscle cell and monocyte migration into the development intima by limiting extracellular matrix remodeling.
  • Coadministration of both agents will limit the development of new lesions by inhibiting cellular accumulation and stabilize the developed lesions by preventing both matrix remodeling and reducing the number of lipid-filled monocyte-macrophages, a source of MMP-7 and -9.
  • the instant invention is a method for treating and/or preventing atherosclerotic lesions comprising coadministrating one or more MMP inhibitors and one or more ACAT inhibitors.
  • the invention is further a method for preventing plaque rupture and for promoting lesion regression by administering a combination of an ACAT inhibitor and an MMP inhibitor.
  • the method is practiced by administering a chemical compound effective in inhibiting the biological activity of a matrix metalloproteinase such as collagenase, stromelysin, gelatinase, or elastase.
  • a matrix metalloproteinase such as collagenase, stromelysin, gelatinase, or elastase.
  • the numerous compounds known to be matrix metalloproteinase inhibitors are useful in the practice of this invention.
  • the method is practiced by administering a chemical compound which inhibits the enzyme acyl-coenzyme A. holesterol acyltransferase.
  • ACAT inhibitors are useful in the practice of this invention.
  • a '"matrix metalloproteinase inhibitor as used herein is any chemical compound that inhibits by at least five percent the hydrolytic activity of at least one matrix metalloproteinase enzyme that is naturally occurring in a mammal. Such compounds are also referred to as "MMP inhibitors.” Numerous matrix metalloproteinase inhibitors are known, and all are useful in the method of this invention. For example, 4-biarylbutyric and 5-biarylpentanoic acid derivatives are described in United States Patent Application 339846 filed November 15, 1994, which is inco ⁇ orated herein by reference. The compounds are defined generally as (T) X A-B-D-E-G. Over 400 specific compounds are named, and each is inco ⁇ orated herein and can be employed in this invention. Especially preferred compounds to be utilized include the following:
  • [1,1 '-Biphenyl]-4-butanoic acid 4'-ethyl- ⁇ -(2-methylpropyl)- ⁇ -oxo-;
  • [1,1 '-Biphenyl]-4-butanoic acid 2'-fluoro- -(2-methylpropyl)- ⁇ -oxo-;
  • [1,1 '-Biphenyl]-4-butanoic acid 4 -methyl- ⁇ -(2-methylpropyl)- ⁇ -oxo-;
  • [1,1 '-Biphenyl]-4-butanoic acid cx-(2-methyl-propyl)- ⁇ -oxo-4'-pentyl-;
  • 2-Furancarboxylic acid 5-[4-(3-carboxy- 1 -oxo-6-phenylhexyl)phenyl]-; Benzenepentanoic acid, ⁇ - [2-oxo-2- [4-(3 -pyridinyl)phenyl] ethyl] -; Benzenepentanoic acid, ⁇ -[2-oxo-2-[4-[6-(pentyloxy)-3-pyridinyl]- phenyl] ethyl]-; [l,l'-Biphenyl]-4-butanoic acid, ⁇ -oxo-4'-(pentylthio)- ⁇ -(3- phenylpropyl) ;
  • [1,1 '-Biphenyl]-4-butanoic acid 4'-methoxy- ⁇ -oxo- ⁇ -(3-phenylpropyl)-;
  • [l,l'-Biphenyl]-4-butanoic acid 3'-chloro-4'-fluoro- ⁇ -oxo- ⁇ -(3- phenylpropyl)-;
  • Benzenepentanoic acid ⁇ -[2-oxo-2-[4-(3-thienyl)phenyl]ethyl]-; [1,1 '-Biphenyl] -4-butanoic acid, 2',4'-dichloro- ⁇ -oxo- ⁇ -(3 -phenylpropyl)-; [1,1 '-Biphenyl] -4-butanoic acid, 4'-formyl- ⁇ -oxo- ⁇ -(3-phenylpropyl)-; [1,1 '-Biphenyl] -4-butanoic acid, ⁇ -oxo- ⁇ -(3-phenylpropyl)-3',5'- bis(trifluoromethyl)-;
  • [1,1 '-Biphenyl] -4-butanoic acid 2'-formyl- ⁇ -oxo- ⁇ -(3-phenylpropyl)-;
  • [1,1 '-Biphenyl]-4-butanoic acid 4-hydroxy- ⁇ -oxo- -(3-phenylpropyl)-;
  • [1,1 '-Biphenyl] -4-butanoic acid ⁇ -oxo- ⁇ -(3-phenylpropyl)-4'-propoxy-
  • [l ,l'-Biphenyl]-4-butanoic acid ⁇ -oxo-4'-(pentyloxy)- ⁇ -(3- phenylpropyl)-;
  • [1,1 '-Biphenyl] -4-butanoic acid ⁇ -oxo-4'-(pentyloxy)- ⁇ -(3- phenylpropyl)-, (S)-;
  • [l,l'-Biphenyl] -4-butanoic acid ⁇ -oxo-4'-(pentyloxy)- ⁇ -(3- phenylpropyl)-, (R)-;
  • [1,1 '-Biphenyl] -4-butanoic acid 4'-(hexyloxy)- ⁇ -oxo- ⁇ -(3-phenylpropyl)-;
  • [1,1 '-Biphenyl] -4-butanoic acid 4'-butoxy- ⁇ -oxo- ⁇ -(3-phenylpropyl)-;
  • [1,1 '-Biphenyl]-4-butanoic acid 4'-chloro- ⁇ -[2-(3-iodophenyl)ethyl]- ⁇ -oxo-;
  • [1,1 '-Biphenyl]-4-butanoic acid 4'-chloro- ⁇ -[2-(4-iodophenyl)ethyl]- ⁇ -oxo-;
  • [1,1 '-Biphenyl]-4-butanoic acid 4'-bromo- ⁇ -oxo- ⁇ -(3-phenylpropyl)-; [l,l'-Biphenyl]-4-butanoic acid, - ⁇ -oxo- ⁇ -(3 -phenylpropyl)-; [1,1 '-Biphenyl]-4-butanoic acid, 4'-amino- ⁇ -oxo- ⁇ -(2-phenylethyl)-;
  • [1,1 '-Biphenyl] -4-butanoic acid 4'-[[(l,l-dimethylethoxy)- carbonyl]amino]- ⁇ -oxo- ⁇ -(2-phenylethyl)-; [1,1 '-Biphenyl]-4-butanoic acid, 4'-(acetylamino) ⁇ -oxo- ⁇ -
  • [1,1 '-Biphenyl] -4-butanoic acid ⁇ -[2-(2-carboxyphenyl)ethyl]-4'-chloro- ⁇ -oxo-;
  • [1 ,1 '-Biphenyl] -4-butanoic acid 4'-chloro- ⁇ -[2-[2-[(diethylamino)- carbonyl]phenyl]ethyl]- ⁇ -oxo-;
  • Cyclopentanecarboxylic acid 2-[(4'-chloro[ 1 , 1 '-biphenyl] -4-yl)carbonyl]- 5- [(phenylmethoxy)methyl] -, ( 1 ,2 ⁇ ,5 ⁇ )-;
  • Cyclopentanecarboxylic acid 2-[(4'-chloro[ 1 , 1 '-biphenyl] -4-yl)carbonyl]- 5-(phenoxymethyl)-, (l ,2 ⁇ ,5 ⁇ )-; Cyclopentanecarboxylic acid, 2-[(benzoyloxy)-methyl]-5-[(4'-chloro[l,l'- bi ⁇ henyl]-4-yl)carbonyl]-, (1 ⁇ ,2 ⁇ ,5 ⁇ )-; 1 ,2-Benzenedicarboxylic acid, 1 -[[2-carboxy-3-[(4'-chloro[ 1 , 1 '-biphenyl]- 4-yl)carbonyl]cyclopentyl]-methyl]-2-methyl ester,( 1 ⁇ ,2 ⁇ ,3 ⁇ )-;
  • Cyclopentanecarboxylic acid 2-[(4'-chloro[ 1 , 1 '-biphenyl] -4-yl)carbonyl]- 5-[(2-thienylthio)methyl]-, (l ⁇ ,2 ⁇ ,5 ⁇ )-; Cyclopentanecarboxylic acid, 2-[(benzoylamino)methyl]-5-[(4'- chloro[ 1 , 1 '-biphenyl]-4-yl)carbonyl]-, (1 ⁇ ,2 ⁇ ,5 ⁇ )-;
  • Cyclopentanecarboxylic acid 2-[(4'-chloro[ 1 , 1 '-biphenyl]-4-yl)carbonyl]- 5 - [ [(2-methoxyethoxy)methoxy] methyl] -, (l ⁇ ,2 ⁇ ,5 ⁇ )-;
  • Cyclopentanecarboxylic acid 2-[(4'-chloro[ 1 , 1 '-biphenyl]-4-yl)carbonyl]- 5-[[(phenylmethyl)thio]methyl]-, (l ⁇ ,2 ⁇ ,5 ⁇ )-;
  • Cyclopentanecarboxylic acid 2-[(4'-chloro[ 1 , 1 '-biphenyl]-4-yl)carbonyl]- 5-[(phenylthio)methyl]-, (loc,2 ⁇ ,5 ⁇ )-;
  • Cyclopentanecarboxylic acid 2-[(4'-chloro[l , l'-biphenyl]-4-yl)carbonyl]- 5-[(propylthio)methyl]-, (l ⁇ ,2 ⁇ ,5 ⁇ )-; Cyclopentanecarboxylic acid, 2-[(2-benzothiazolylthio)methyl]-5-[(4'- chloro[l,l'-biphenyl]-4-yl)carbonyl]-, (l ,2 ⁇ ,5 ⁇ )-;
  • Benzoic acid 2-[[[2-carboxy-3-[(4'-chloro[l,l'-biphenyl]- 4-yl)carbonyl]cyclopentyl]methyl]thio]-, 1 -methyl ester, (l ⁇ ,2 ⁇ ,3 ⁇ )-;
  • Cyclopentanecarboxylic acid 2-[(4'-chloro[ 1 , 1 '-biphenyl]-4-yl)carbonyl]- 5-[[[(phenylmethoxy)carbonyl]-amino]methyl]-, (l ⁇ ,2 ⁇ ,5 ⁇ )-;
  • Benzoic acid 3-methyl-, [2-carboxy-3-[(4'-chloro[l,l'-biphenyl]- 4-yl)carbonyl]cyclopentyl]rnethyl ester, (l ⁇ ,2 ⁇ ,3 ⁇ )-; Benzoic acid, 4-methyl-, [2-carboxy-3-[(4'-chloro[ 1 , 1 '-biphenyl]-
  • Benzoic acid 3-methoxy-, [2-carboxy-3-[(4'-chloro [1,1 '-biphenyl] - 4-yl)carbonyl]cyclopentyl]methyl ester, (l ⁇ ,2 ⁇ ,3 ⁇ )-;
  • Cyclopentanecarboxylic acid 2-[(2-benzoxazolylthio)methyl]-5-[(4'- chloro[l,l'-biphenyl]-4-yl)carbonyl]-, (l ⁇ ,2 ⁇ ,5 ⁇ )-; Cyclopentanecarboxylic acid, 2-[(4'-chloro[ 1 , 1 '-biphenyl]-4-yl)carbonyl]-
  • Cyclopentanecarboxylic acid 2-[(4'-chloro[ 1 , 1 '-biphenyl]-4-yl)carbonyl]- 5-[(l,3-dihydro-5-nitro-l,3-dioxo-2H-isoindol-2-yl)methyl]-, (l ⁇ ,2 ⁇ ,5 ⁇ )-;
  • [1,1 '-Biphenyl] -4-butanoic acid -(acetylamino)-4'-chloro- ⁇ -oxo-; 2/ -Isoindole-2-hexanoic acid, -[2-(4'-chloro[ 1 , 1 '-biphenyl] -4-yl)- 2 -oxoethyl] -1,3 -dihydro- 1 ,3 -dioxo- ;
  • [1,1 '-Biphenyl]-4-butanoic acid 4'-chloro- ⁇ -[2-[3-[(diethylamino)- carbonyl]phenyl] ethyl] - ⁇ -oxo- ;
  • [1,1 '-Biphenyl] -4-butanoic acid ⁇ -[2-[3-[(butylamino)carbonyl]- phenyl]ethyl]-4'-chloro- ⁇ -oxo-;
  • [1,1 '-Biphenyl]-4-butanoic acid 4'-methoxy- ⁇ -oxo- ⁇ -(2-phenyl ethyl)-; [1,1 '-Biphenyl]-4-butanoic acid, 4'-hydroxy- ⁇ -oxo- ⁇ -(2-phenylethyl)-; [1,1 '-Biphenyl]-4-butanoic acid, 4'-ethoxy- ⁇ -oxo- ⁇ -(2-phenylethyl)-;
  • [1,1 '-Biphenyl] -4-butanoic acid ⁇ -oxo- ⁇ -(2-phenylethyl)-4'-propoxy-; [1,1 '-Biphenyl] -4-butanoic acid, ⁇ -oxo-4'-(pentyloxy)- ⁇ -(2-phenylethyl)-; [1,1 '-Biphenyl]-4-butanoic acid, 4'-(hexyloxy)- ⁇ -oxo- ⁇ -(2-phenylethyl)-; [1,1 '-Biphenyl]-4-butanoic acid, 4'-butoxy- ⁇ -oxo- -(2-phenylethyl)-; [1,1 '-Biphenyl] -4-butanoic acid, ⁇ -oxo- ⁇ -(2-phenylethyl)-4'-
  • [1,1 '-Biphenyl] -4-butanoic acid -[2-(3-iodophenyl)ethyl]- ⁇ -oxo-4'- (phenylmethoxy)-;
  • [1,1 '-Biphenyl] -4-butanoic acid ⁇ -[2-(3-[(diethylamino)carbonyl]- phenyl]ethyl]- ⁇ -oxo-4'-(pentyloxy)-;
  • [1,1 '-Biphenyl] -4-butanoic acid 4'-chloro- ⁇ -heptyl- ⁇ -oxo-; [l,l'-Biphenyl]-4-butanoic acid, 4'-chloro- -decyl - ⁇ -oxo-; [1,1 '-Biphenyl]-4-butanoic acid, 4'-nitro- ⁇ -oxo- -(2-phenyl ethyl)-; [1,1 '-Biphenyl] -4-butanoic acid, 4'-cyano- ⁇ -oxo- ⁇ -(2-phenylethyl)-; [1,1 '-Biphenyl] -4-butanoic acid, 4'-chloro- ⁇ -[2-(2-iodophenyl)ethyl]- ⁇ - oxo-;
  • [l,l'-Biphenyl]-4-butanoic acid 4'-chloro- ⁇ -oxo- -phenyl-; [1,1 '-Biphenyl]-4-butanoic acid, 4'-chloro- ⁇ -oxo- ⁇ -(phenylmethyl)-; [1,1 '-Biphenyl] -4-butanoic acid, 4'-chloro- ⁇ -oxo- ⁇ -(2-phenylethyl)-;
  • [1,1 '-Biphenyl]-4-butanoic acid 4'-bromo- ⁇ -oxo- ⁇ -(3-phenylpropyl)-; [1,1 '-Biphenyl] -4-butanoic acid, ⁇ -oxo- ⁇ -(3-phenylpropyl)-; [1,1 '-Biphenyl]-4-butanoic acid, 4'-amino- ⁇ -oxo- ⁇ -(2-phenylethyl)-;
  • [1 ,1 '-Biphenyl] -4-butanoic acid 4'-[[(l,l-dimethylethoxy)- carbonyl]amino]- ⁇ -oxo- ⁇ -(2-phenylethyl)-; [1,1 '-Biphenyl] -4-butanoic acid, 4'-(acetylamino)- ⁇ -oxo- ⁇ -
  • [1,1 '-Biphenyl]-4-butanoic acid ⁇ -[2-(2-carboxyphenyl)ethyl]-4'-chloro- ⁇ -oxo-;
  • [1,1 '-Biphenyl]-4-butanoic acid 4'-chloro- ⁇ -[2-[2-[(diethylamino)- carbonyl)phenyl] ethyl] - ⁇ -oxo- ;
  • peptides are known matrix metalloproteinase inhibitors. Typical of such peptides are those described in United States Patent Number 5,300,501 ; 5,530,128; 5,455,258; 5,552,419; WO 95/13289; and WO 96/1 1209, all of which are inco ⁇ orated herein by reference. Such compounds are illustrated by the formula
  • variable groups can include hydrogen alkyl, aryl, heteroaryl, alkenyl, alkynyl, carboxy, and the like.
  • Preferred compounds from within this class which can be utilized in the method of this invention include the following: N- [2 ,3 -bis- Acetylmercaptopropanoyl] -L-leucyl-L-pheny lalanine N-methylamide;
  • N-(Acetylmercaptoacyl)-L-leucyl-L-tryptophan methylamide (RS)-2-Mercaptopentanoyl-L-leucyl-L-phenylalanine N-methylamide; (RS)-2-Mercaptopropanoyl-L-leucyl-L-phenylalanine N-methylamide; (RS)-2-Mercapto-3-methylbutanoyl-L-leucyl-L-phenylalanine N-methylamide;
  • N-phenylamide N-[l(R)-Carboxy-ethyl]- ⁇ -(S)-(2-phenyl-ethyl)glycine-(L)-phenylalanine, N-phenylamide;
  • N-phenylamide (2-((Hydroxy(methyl)phosphinyl)methyl)-4-phenylbutanoyl)-L-leucine, N-phenylamide;
  • 1,5-pentanedioic acid 1 -(L-leucine, N-phenylamide)amide
  • 1,5-pentanedioic acid 1 -(L-leucine, N-phenylamide)amide
  • inhibitors of matrix metalloproteinases are known.
  • a large number of inhibitors are characterized as hydroxamic acid-based and/or carboxylic acid-based compounds. Typical of such compounds are those described in the following references, all of which are inco ⁇ orated herein by reference, since all of the disclosed compounds can be used in the method of this invention.
  • aryl sulfonamides of the formula where Ar is carbocyclic or heterocyclic aryl, and R, Rl, and R 2 include hydrogen, alkyl, aryl, heteroaryl, amino, substituted and disubstituted amino. These compounds are disclosed in European Patent Number 0606046, inco ⁇ orated herein by reference. Specific compounds to be employed in the present method include:
  • Rl, R 2 , R- , and R 4 can be hydrogen or alkyl and X is OR ⁇ or NHR5 where R ⁇ includes hydrogen, alkyl and aryl, A includes alkyl, and n is
  • Typical compounds to be employed in the instant method include the following:
  • tricyclic butyric acid derivatives which are inhibitors of matrix metalloprotienases are employed in the instant invention.
  • a preferred group of tricyclic butyric acid derivatives are defined by the formula:
  • n is zero or an integer of 1 to 5, alkyl, or -(CH 2 ) n -cycloalkyl wherein n is as defined above, or N-N-R ⁇ wherein R6 and R ⁇ a are each the same or different and
  • R6a each is as defined above for R ⁇ ; R and R a are each the same or different and each is hydrogen,
  • n is as defined above
  • n is as defined above
  • R 7 is O or S and p or q is each zero or an integer of 1 to 5 and the sum of p + q equals an integer of 5, -(CH 2 )p-R ⁇ "(CH 2 )q-heteroaryl wherein p, q, and R 7 are as defined above, alkyl, -(CH ) n -cycloalkyl wherein n is as defined above, or
  • r is an integer of 1 to 9; a is zero or an integer of 1 to 3; R 5 is OH,
  • R 6a the same or different and are as defined above for R ⁇ , or
  • R3 and R 4 are each the same or different and each is hydrogen, alkyl,
  • R ⁇ and R ⁇ are each the same or
  • R 6a different and are as defined above for R ⁇ , or -(CH 2 ) n -N-R 6 wherein R 6 and ROa are each the same or
  • R 6a different and are as defined above for R ⁇ ;
  • W, Wl, Z, and Z ⁇ are each the same or different and each is CR- wherein R 3 is as defined above, or

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Furan Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
PCT/US1999/013948 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions WO2000004892A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
PL99346011A PL346011A1 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
HR20010055A HRP20010055A2 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
AU47017/99A AU4701799A (en) 1998-07-21 1999-06-18 Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions
BR9912296-0A BR9912296A (pt) 1998-07-21 1999-06-18 Co-adminiostração de inibidores acat e mmp para o tratamento de lesões ateroscleróticas
EA200100153A EA200100153A1 (ru) 1998-07-21 1999-06-18 Совместное назначение ингибиторов асат и ммр для лечения атеросклеротических поражений
KR1020017000930A KR20010083134A (ko) 1998-07-21 1999-06-18 아테롬성 동맥경화증 병소의 치료를 위한 ａｃａｔ 및ｍｍｐ 억제제의 병용 투여
SK50-2001A SK502001A3 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
EEP200100046A EE200100046A (et) 1998-07-21 1999-06-18 ACAT ja MMP inhibiitorite koosmanustamine aterosklerootiliste kahjustuste raviks
JP2000560885A JP2002521328A (ja) 1998-07-21 1999-06-18 アテローム性動脈硬化症病変の治療のためのａｃａｔ阻害剤およびｍｍｐ阻害剤の併用投与
APAP/P/2001/002035A AP2001002035A0 (en) 1998-07-21 1999-06-18 Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions.
IL14098299A IL140982A0 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
CA002335062A CA2335062A1 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
EP99930483A EP1098662A2 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
IS5809A IS5809A (is) 1998-07-21 2001-01-12 Samtíma inngjöf ACAT og MMP tálma til meðhöndlunar á skemmdum vegna fituhrörnunar
BG105162A BG105162A (en) 1998-07-21 2001-01-17 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
NO20010291A NO20010291D0 (no) 1998-07-21 2001-01-18 Coadministrasjon av ACAT og MMP inhibitorer for behandling av aterosklerotiske sår

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21
US60/093,639 1998-07-21

Publications (2)

Publication Number Publication Date
WO2000004892A2 true WO2000004892A2 (en) 2000-02-03
WO2000004892A3 WO2000004892A3 (en) 2000-05-18

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/013948 WO2000004892A2 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Country Status (25)

Country Link
EP (1) EP1098662A2 (cs)
JP (1) JP2002521328A (cs)
KR (1) KR20010083134A (cs)
CN (1) CN1310629A (cs)
AP (1) AP2001002035A0 (cs)
AU (1) AU4701799A (cs)
BG (1) BG105162A (cs)
BR (1) BR9912296A (cs)
CA (1) CA2335062A1 (cs)
CZ (1) CZ2001126A3 (cs)
EA (1) EA200100153A1 (cs)
EE (1) EE200100046A (cs)
HR (1) HRP20010055A2 (cs)
HU (1) HUP0102880A3 (cs)
ID (1) ID30030A (cs)
IL (1) IL140982A0 (cs)
IS (1) IS5809A (cs)
NO (1) NO20010291D0 (cs)
OA (1) OA11584A (cs)
PL (1) PL346011A1 (cs)
SK (1) SK502001A3 (cs)
TR (1) TR200100205T2 (cs)
WO (1) WO2000004892A2 (cs)
YU (1) YU3501A (cs)
ZA (1) ZA200100294B (cs)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034127A1 (en) * 1999-11-05 2001-05-17 Warner-Lambert Company Prevention of plaque rupture by acat inhibitors
WO2001044179A1 (en) * 1999-12-17 2001-06-21 Versicor, Inc. Novel succinate compounds, compositions and methods of use and preparation
US6544987B2 (en) 1999-12-01 2003-04-08 Pfizer Inc. Compounds, compositions, and methods for stimulating neuronal growth and elongation
EP1314423A4 (en) * 2000-09-01 2004-05-19 Sankyo Co MEDICAL CONNECTIONS
WO2004007444A3 (en) * 2002-07-11 2004-09-10 Vicuron Pharm Inc N-hydroxyamide derivatives possessing antibacterial activity
JP2005527556A (ja) * 2002-04-03 2005-09-15 トポターゲット ユーケー リミテッド Ｈｄａｃ阻害剤としてのピペラジン結合を有するカルバミン酸化合物
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
US8057814B2 (en) 2001-01-11 2011-11-15 Abbott Laboratories Drug delivery from stents
WO2016113713A1 (en) * 2015-01-15 2016-07-21 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104211695B (zh) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 一组胺甲酰基苯磺酰类化合物的用途
CN106831697B (zh) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 川榛有效提取成分及其在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
CA2221729A1 (en) * 1995-08-04 1997-02-20 Warner-Lambert Company Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels
DE69707865T2 (de) * 1996-05-17 2002-05-02 Warner-Lambert Co., Morris Plains Biphenylsulfonamid matrix metalloproteinase inhibitoren
BR9711988A (pt) * 1996-09-04 1999-08-24 Warner Lambert Co Inibidores de metaloproteinase de matriz e seus empregos terap-uticos

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034127A1 (en) * 1999-11-05 2001-05-17 Warner-Lambert Company Prevention of plaque rupture by acat inhibitors
US6544987B2 (en) 1999-12-01 2003-04-08 Pfizer Inc. Compounds, compositions, and methods for stimulating neuronal growth and elongation
WO2001044179A1 (en) * 1999-12-17 2001-06-21 Versicor, Inc. Novel succinate compounds, compositions and methods of use and preparation
EP1314423A4 (en) * 2000-09-01 2004-05-19 Sankyo Co MEDICAL CONNECTIONS
US8057814B2 (en) 2001-01-11 2011-11-15 Abbott Laboratories Drug delivery from stents
JP2005527556A (ja) * 2002-04-03 2005-09-15 トポターゲット ユーケー リミテッド Ｈｄａｃ阻害剤としてのピペラジン結合を有するカルバミン酸化合物
WO2004007444A3 (en) * 2002-07-11 2004-09-10 Vicuron Pharm Inc N-hydroxyamide derivatives possessing antibacterial activity
AU2003267991B2 (en) * 2002-07-11 2009-10-08 Vicuron Pharmaceuticals, Inc. N-hydroxyamide derivatives possessing antibacterial activity
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
WO2016113713A1 (en) * 2015-01-15 2016-07-21 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing

Also Published As

Publication number Publication date
OA11584A (en) 2004-07-20
CA2335062A1 (en) 2000-02-03
JP2002521328A (ja) 2002-07-16
BG105162A (en) 2001-12-29
CZ2001126A3 (cs) 2002-01-16
HUP0102880A2 (en) 2002-06-29
KR20010083134A (ko) 2001-08-31
ID30030A (id) 2001-11-01
ZA200100294B (en) 2002-01-10
HRP20010055A2 (en) 2002-04-30
EA200100153A1 (ru) 2001-08-27
IL140982A0 (en) 2002-02-10
AU4701799A (en) 2000-02-14
IS5809A (is) 2001-01-12
PL346011A1 (en) 2002-01-14
NO20010291L (no) 2001-01-18
WO2000004892A3 (en) 2000-05-18
EP1098662A2 (en) 2001-05-16
CN1310629A (zh) 2001-08-29
HUP0102880A3 (en) 2002-11-28
SK502001A3 (en) 2002-06-04
TR200100205T2 (tr) 2001-05-21
AP2001002035A0 (en) 2001-03-31
NO20010291D0 (no) 2001-01-18
BR9912296A (pt) 2001-04-17
YU3501A (sh) 2005-06-10
EE200100046A (et) 2002-06-17

Similar Documents

Publication Publication Date Title
AU741768B2 (en) Method for treating and preventing heart failure and ventricular dilatation
EP1047450B1 (en) Ace inhibitor-mmp inhibitor combinations
AU737117B2 (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
EP1098662A2 (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
US20020049237A1 (en) Statin-MMP inhibitor combinations
KR20010041916A (ko) 스타틴-매트릭스 메탈로프로테이나제 저해제 복합제제
US20050020607A1 (en) Statin-MMP inhibitor combinations
MXPA01000780A (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
EP1366765A1 (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
HK1038317A (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
MXPA00003736A (en) Ace inhibitor-mmp inhibitor combinations

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-35/01

Country of ref document: YU

Ref document number: 99808958.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AU BA BB BG BR CA CN CU CZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AU BA BB BG BR CA CN CU CZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2335062

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/00019/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 47017/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1200100030

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: PV2001-126

Country of ref document: CZ

Ref document number: 2001/00294

Country of ref document: ZA

Ref document number: 200100294

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 502001

Country of ref document: SK

Ref document number: 1999930483

Country of ref document: EP

Ref document number: 509358

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 1999 105162

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 140982

Country of ref document: IL

Ref document number: 2001/00205

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2000 560885

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P20010055A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 1020017000930

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/000780

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 200100153

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20010138

Country of ref document: UZ

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1999930483

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017000930

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 09744185

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: PV2001-126

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1999930483

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020017000930

Country of ref document: KR